Neutralising antibodies
Induction of neutralising antibodies by virus like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses
7
Analysis of the function of IL-10 in chickens using specific neutralising antibodies and a sensitive capture ELISA
7
Efficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies
9
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
9
Extensive complement dependent enhancement of HIV 1 by autologous non neutralising antibodies at early stages of infection
20
Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules
13
Heterologous protection elicited by candidate monomeric recombinant HIV 1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model
14
Yeast expressed recombinant Hemagglutinin protein of Novel H1N1 elicits neutralising antibodies in rabbits and mice
13
Henipavirus Neutralising Antibodies in an Isolated Island Population of African Fruit Bats
10
Modulation of the virus receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivoescape from neutralising antibody
13
Enhanced neutralising antibody response to bovine viral diarrhoea virus (BVDV) induced by DNA vaccination in calves
22
The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants
5
THE CHARACTERIZATION OF ANTIBODIES TO PENICILLIN
7
Bispecific antibodies and their applications
14
PENICILLIN ANTIBODIES IN CHILDREN
9
Nonprecipitating Insulin Antibodies
5
Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies
36
EFFECTS OF ANTIBODIES ON MITOCHONDRIA
10
THE NORMAL INTESTINAL MICROFLORA AND THE ANTIBODIES (THE ANTIBODIES STUDY tO THE OPPORTUNISTIC INTESTINAL ENTEROBACTERIA)
5
Polyclonal and Monoclonal Antibodies
13